secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2026-01-27T23:59:59+00:00
Accession:  0001193125-26-023339
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo appoints COO and CMO; Eric Adler leaves to lead spin-off Myoventive
-------------------------------------------------------------------------

- Jose Manuel Otero, former CTO, becomes COO effective Jan 2, 2026; base salary set at $510,000.
- Narinder P. Bhalla appointed Chief Medical Officer effective Jan 20, 2026, succeeding Eric Adler.
- Eric Adler steps down as executive officer to become CEO of Myoventive, co-founded by Lexeo, Perceptive Xontogeny, and venBio Partners.
- Adler remains senior clinical and scientific advisor to Lexeo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000119312526023339/0001193125-26-023339-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000119312526023339/lxeo-20260127.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-023339

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer